Mirati gauging sale interest of Big Pharmas — report

Mirati Therapeutics, maker of the experimental cancer drug adagrasib, is piquing the interest of Big Pharmas, according to a report from Bloomberg.

On Tuesday, the biotech’s stock $MRTX rose by almost 16%, jumping from just under $75 to over $86. After Wednesday’s...

Click to view original post